Recent News & Events

June 21, 2023

Marlinz Pharma has successfully moved all of it's non-drug related R&D and production from multiple outside vendors to our own production facility, giving us the ability to maintain quality, control rising costs and eliminate delays.  Equipped with some of the latest high speed, European automatic manufacturing and packaging machines, the facility already employs 12 full time machine operators and administrators.  The facility is set up to handle large increases in volumes for existing and new products and will be certified for the addition of full OTC drug and supplement production in mid-2024.  The opening of our own production facility represents another important milestone in the Marlinz Pharma journey to becoming one of the most innovative, trusted and fastest growing specialty pharmaceutical companies in North America.

November 30, 2022

Marlinz Pharma has reached 1,000,000 units of Tolcylen products dispensed through our healthcare partners as of November 30, 2022.  After nearly 3 years of extensive research and product development that resulted in 5 different USPTO patents issued, the Tolcylen product line was launched in 2017 with a single product, the  Tolcylen Antifungal/Nail Renewal Solution. Since then, Tolcylen Solution has become the number one physician dispensed nail fungus product in the country. Over the last 4 years the Tolcylen Antifungal/Skin Renewal Cream, Shoe Spray, Fungal Eradication Kit and Foot Soak lines have been added to the most researched, clinically proven, exclusively physician dispensed product line available today.

April 15, 2022

Marlinz Pharma continued its strong revenue growth with another year of double digit growth despite economic head winds.  The strong growth came from significant contributions from our core product family and the successful launch of the first and only of their kind, Tolcylen Therapeutic and Daily Use Micro-cleansing Soaks.  Marlinz, through one of its affiliated companies, has broken ground on a new state of the art manufacturing facility that will intially focus on production of footcare products including testing, batching, filling and packaging. The facility, located 2 hours south of our Houston, Texas, corportate offices will feature a dedicated research and development lab to expedite new product development and commercial launches. OTC drug manufacturing capabilites will be added in early 2024. It will also feature an in-house shipping department for the growing Marlinz Pharma product family.  Marlinz Pharma will have the ability to consistently maximize its quality control standards while also keeping costs to a minimum.  The facility is scheduled to open its doors in late 2023.  

February 1, 2022

Marlinz Pharma has launched an innovative foot soak line that utilizes the patented Tolcylen delivery vehicle in combination with exfoliators, moisturizers, cleansers, essential oils, sea salts, and Epsom salts. The Tolcylen Therapeutic Foot Soak is packaged in a carton of 5 single-use pouches and is ideal for short-term augmentation of treatments for typical skin and nail conditions and as a deep cleansing soak. The Tocylen Daily-Use Foot Soak is packaged in a large resealable bag and is formulated to be used routinely over an extended period of time to maintain optimal foot hygiene by cleansing, moisturizing, and protecting the skin and nails. 

October 22, 2021

The Tolcylen® Onychomycosis study is following all FDA Phase II requirements and has added new sites to enhance enrollment to accelerate reaching the 144 total patient target at completion.  The 9-month trial is being led by the primary investigators, Scot Malay DPM and Peter Bregman DPM, and is scheduled to be completed in the fall of 2022.  The study was originally scheduled to be completed in 2021 but was delayed due to the Covid outbreak.

July 10, 2021

Marlinz Pharma’s Intellectual property team has gained the initial approval to file for foreign patent coverage of the Tolcylen® Antifungal/Nail Renewal Solution formulation.  The new round of applications for coverage includes Japan, Australia, Canada, Korea, Russia, India, Mexico and countries of the European Patent Union.  Over the past 3 years Marlinz Pharma has been awarded 5 different patents related to the innovative, first of their kind formulations of combined drugs, cosmetic and low surface tension delivery vehicle ingredients. The ability to emulsify unique combinations of ingredients into single, homogenous formulations has helped create better patient outcomes ranging from minor cosmetic conditions to chronic issues many have had to endure for decades.

March 5, 2021

Marlinz Pharma has announced another significant milestone as Tolcylen™ products dispensed through our physician partners have reached a total of 750,000.  The Tolcylen™ product family continues to experience a repidly expanding customer base with over 99% account retention.  The entire Marlinz Pharma team would like to thank all of our dispensing partners for their continued support. 

December 22, 2020 

Marlinz Pharma has continued to refer a growing number of patients seeking Tolcylen™ to a dispensing physician near them.  Internet search traffic for Tolcylen™ availability has hit an all time high and Marlinz Pharma is now referring up to 150 patients a month by phone, website, email and other communications.  To date over 3,200 total patient referrals have been made to Tolcylen™ diapensing clinics.

October 16, 2020

Marlinz Pharma officials have executed a 5 year lease for a dedicated warehouse space with offices, climate controlled storage and loading docks to handle increased volume over the coming years.  The additional space will also house a chemical prep and formulation lab and small scale production capabilities for future vertical integration plans.  This is another major step in establishing the infrastructure to handle our future growth and quality control needs.

October 1, 2020

Marlinz Pharma closed the 3rd Quarter of 2020 with a record month.  June 2020 revenues beat the previous single month record by over 35%.  With clinics being restricted or in some cases closed, and all trade shows, speaker events, sales rep calls and other meetings cancelled from March 15^th on, Tolcylen™ revenues still outpaced all previous months.  The unexpected growth during the pandemic was possible only through strong brand loyalty and the ability of our dispensing partners to navigate pandemic restrictions while continuing to offer their patients safe, accessible care.